Nature

Atovaquone-induced oxidative stress activates the pentose phosphate pathway and Immunogenic cell death in ovarian cancer

Atovaquone, an FDA-approved oxidative phosphorylation (OXPHOS) inhibitor, has shown promise in the treatment of epithelial ovarian cancer (EOC), the deadliest gynecologic malignancy. However, the ...
Nature

TMEM45A enhances palbociclib resistance and cellular glycolysis by activating AKT/mTOR signaling pathway in HR+ breast cancer

Palbociclib, a CDK4/6 inhibitor, plays a crucial role in the treatment of HR+ breast cancer. However, resistance to palbociclib is a significant concern that merits further investigation. Our ...
ascopubs.org

Clinical outcomes of patients with cell cycle alterations by treatment type: The MD Anderson Cancer Center IMPACT 2 study.

Multi-modal molecular profiling of CDH1 and CLDN18.2 to identify predictive biomarkers for zolbetuximab efficacy in patients with advanced gastric adenocarcinoma: The ZOL-C3 study.
Medical Xpress

Inflammation and metabolic stress combine to drive a new cell death pathway—mitoxyperilysis

In several disease conditions, including infections and cancers, innate immune activation and nutrient scarcity occur together. A study from St. Jude Children's Research Hospital, published in Cell, ...
EurekAlert!

CNDP2 activates the MAPK pathway and arrests the cell cycle, acting as a functional tumor suppressor in gastric cancer. (IMAGE)

Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.